Amy Abernethy (Photographer: Andrew Harrer/Bloomberg via Getty Images)
June 3, 2021 09:27 AM EDTUpdated June 4, 02:33 PM
People
FDA+

For­mer FDA No. 2 Amy Aber­nethy re­joins Robert Califf at Google's Ver­i­ly, hop­ping aboard as clin­i­cal R&D head

Zachary Brennan

Senior Editor

Google’s life sci­ences com­pa­ny Ver­i­ly on Thurs­day tapped for­mer prin­ci­pal deputy FDA com­mis­sion­er Amy Aber­nethy as pres­i­dent of its clin­i­cal re­search busi­ness.

The move means …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times